Rapid take-up of Dupixent in atopic dermatitis and asthma caused sales ... a series of other follow-up indications that involve type 2 inflammation that occurs in allergic-type diseases.

The total market size of eosinophilic esophagitis in 2023 was approximately USD 1.80 trillion in the 7MM, which is expected to grow during the forecast period (2020-2034). Among EU4 and the UK, ...

Eylea is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications ... of Dupixent (approved for use in certain patients with atopic dermatitis, asthma ...

Dupixent is already approved to treat atopic dermatitis, as well as other indications involving type 2 inflammation, including severe asthma ... Development in peanut allergy has also been ...

“Both companies are ‘houses of brands’, in other words a collection of well-diversified luxury businesses serving multiple ...

That includes the approval of "innovative" drugs like Tryvio for high blood pressure, Neffy for severe allergic reactions and Dupixent for ... by clinical treatment guidelines or mainstay medical ...

If that doesn't work, your doctor may give you a shot of a medicine called dupilumab (Dupixent ... if you live in a dry climate. Treat allergies and asthma. Continue using a corticosteroid ...

He added that most patients have a genetic predisposition, with other family members also having atopic dermatitis or other atopic conditions such as allergic rhinitis (sinus), asthma and allergic ...

[32] Therefore, chronic urticaria and/or angioedema are not considered indications ... of asthma[100,101] 1965: Lowell and Franklin demonstrated the specificity of immunotherapy in ragweed ...

According to GlobalData, Phase II drugs for Unspecified Respiratory Disorders does not have sufficient historical data to build an indication ... treatment of asthma, atopic dermatitis (atopic eczema) ...